Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting ...
Net income and earnings per share ("EPS")* were $19.4 million and $0.82, respectively, for the third quarter of 2025 and $94.2 million and $4.03, respectively, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback